Tagraxofusp: Safety and Efficacy of Combing TAG with AZA and AZA+VEN
Safety and Efficacy of Combining Tagraxofusp with AZA or AZA+VEN in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN. ASH 2021. Poster
EMERALD: Phase 3 Results in ER+/HER2- advanced/metastatic breast cancer (mBC)
Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on priorendocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial. SABCS 2021. Oral Presentation
Tagraxofusp: A Multicenter Phase 1/2 Trial in Patients with Poor-Risk MF
A Multicenter Phase 1/2 Trial of Tagraxofusp in Patients with Poor-Risk MF. ASH 2020. Poster
Phase 1: Final Analysis of ELACESTRANT in ER+/HER2- Advanced Breast Cancer
Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. SABCS 2019. Poster
Tagraxofusp Alone and in Combination with Ruxolitinib for Treatment of Myeloproliferative Neoplasms
Evaluation of Tagraxofusp(SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms. ASH 2019. Poster
Results from Clinical Trial of Tagraxofusp in Patients with Intermediate or High Risk R/R MF
Results from Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. ASH 2019. Oral Presentation
Tagraxofusp in Combination with POM/DEX in Relapsed or Refractory Multiple Myeloma
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. ASH 2019. Poster
CD123+ plasmacytoid dendritic cells (pDCs) from SSc patients are susceptible to tagraxofusp
CD123+ plasmacytoid dendritic cells (pDCs) from SSc patients are susceptible to tagraxofusp. ACR 2019. Poster
Outcomes of Tagraxofusp (SL-401) in Older Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Outcomes of Tagraxofusp (SL-401) in Older Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). JSH 2019. Presentation
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors. ESMO 2019. POSTER